Flavone acetic acid--preclinical and clinical activity - PubMed (original) (raw)
Review
Flavone acetic acid--preclinical and clinical activity
D J Kerr et al. Eur J Cancer Clin Oncol. 1989 Sep.
No abstract available
Similar articles
- Flavonoids: a new class of anticancer agents? Preclinical and clinical data of flavone acetic acid.
Armand J, De Forni M, Recondo G, Cals L, Cvitkovic E, Munck J. Armand J, et al. Prog Clin Biol Res. 1988;280:235-41. Prog Clin Biol Res. 1988. PMID: 3051027 Review. No abstract available. - Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.
O'Dwyer PJ, Shoemaker D, Zaharko DS, Grieshaber C, Plowman J, Corbett T, Valeriote F, King SA, Cradock J, Hoth DF, et al. O'Dwyer PJ, et al. Cancer Chemother Pharmacol. 1987;19(1):6-10. doi: 10.1007/BF00296246. Cancer Chemother Pharmacol. 1987. PMID: 3545524 Review. - Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice.
Plowman J, Narayanan VL, Dykes D, Szarvasi E, Briet P, Yoder OC, Paull KD. Plowman J, et al. Cancer Treat Rep. 1986 May;70(5):631-5. Cancer Treat Rep. 1986. PMID: 3708611 - Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.
Kerr DJ, Maughan T, Newlands E, Rustin G, Bleehen NM, Lewis C, Kaye SB. Kerr DJ, et al. Br J Cancer. 1989 Jul;60(1):104-6. doi: 10.1038/bjc.1989.230. Br J Cancer. 1989. PMID: 2803908 Free PMC article. - Clinical and pharmacokinetic phase I trial with the diethylaminoester of flavone acetic acid (LM985, NSC 293015).
Dodion PF, Abrams J, Gérard B, Crespeigne N, Peeters B, Van Berchem C, Kenis Y. Dodion PF, et al. Eur J Cancer Clin Oncol. 1987 Jun;23(6):837-42. doi: 10.1016/0277-5379(87)90288-4. Eur J Cancer Clin Oncol. 1987. PMID: 3653200
Cited by
- Agonists and Inhibitors of the cGAS-STING Pathway.
Yu X, Cai L, Yao J, Li C, Wang X. Yu X, et al. Molecules. 2024 Jun 30;29(13):3121. doi: 10.3390/molecules29133121. Molecules. 2024. PMID: 38999073 Free PMC article. Review. - Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy.
Garland KM, Sheehy TL, Wilson JT. Garland KM, et al. Chem Rev. 2022 Mar 23;122(6):5977-6039. doi: 10.1021/acs.chemrev.1c00750. Epub 2022 Feb 2. Chem Rev. 2022. PMID: 35107989 Free PMC article. Review. - The cGAS/STING Pathway: A Novel Target for Cancer Therapy.
Gan Y, Li X, Han S, Liang Q, Ma X, Rong P, Wang W, Li W. Gan Y, et al. Front Immunol. 2022 Jan 3;12:795401. doi: 10.3389/fimmu.2021.795401. eCollection 2021. Front Immunol. 2022. PMID: 35046953 Free PMC article. Review. - The STING1 network regulates autophagy and cell death.
Zhang R, Kang R, Tang D. Zhang R, et al. Signal Transduct Target Ther. 2021 Jun 2;6(1):208. doi: 10.1038/s41392-021-00613-4. Signal Transduct Target Ther. 2021. PMID: 34078874 Free PMC article. Review. - Anticancer flavonoids are mouse-selective STING agonists.
Kim S, Li L, Maliga Z, Yin Q, Wu H, Mitchison TJ. Kim S, et al. ACS Chem Biol. 2013 Jul 19;8(7):1396-401. doi: 10.1021/cb400264n. Epub 2013 May 23. ACS Chem Biol. 2013. PMID: 23683494 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources